| Schedule of segment information |
| | | | | | | | | | | | | | | Six Months Ended June 30, 2025 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Revenue from external customers | | 44,408 | | 99,039 | | 143,447 | | 134,230 | | — | | 277,677 | Cost of revenue | | — | | (38,223) | | (38,223) | | (129,354) | | — | | (167,577) | Research and development expenses | | (71,990) | | — | | (71,990) | | — | | — | | (71,990) | Selling expenses | | — | | (11,828) | | (11,828) | | (2,045) | | — | | (13,873) | Administrative expenses | | (14,599) | | (1,564) | | (16,163) | | (2,222) | | (9,366) | | (27,751) | Gain on divestment of an equity investee | | — | | — | | — | | 477,456 | | — | | 477,456 | Interest income | | 509 | | — | | 509 | | 57 | | 19,023 | | 19,589 | Interest expense | | (1,033) | | — | | (1,033) | | (257) | | (175) | | (1,465) | Equity in earnings of an equity investee, net of tax | | — | | — | | — | | 23,125 | | — | | 23,125 | Income tax expense | | (394) | | (67) | | (461) | | (61,614) | | (1,087) | | (63,162) | Other segment items | | (2,612) | | (74) | | (2,686) | | 928 | | 4,683 | | 2,925 | Net (loss)/income attributable to the Company | | (45,711) | | 47,283 | | 1,572 | | 440,304 | | 13,078 | | 454,954 | Depreciation/ amortization | | (5,602) | | (422) | | (6,024) | | (51) | | (43) | | (6,118) | Additions to non-current assets (other than financial instruments and deferred tax assets) | | 5,649 | | 10,000 | | 15,649 | | 150 | | — | | 15,799 |
| | | | | | | | | | | | | | | Six Months Ended June 30, 2024 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Revenue from external customers | | 40,841 | | 127,796 | | 168,637 | | 137,044 | | — | | 305,681 | Cost of revenue | | — | | (48,458) | | (48,458) | | (131,677) | | — | | (180,135) | Research and development expenses | | (95,256) | | — | | (95,256) | | — | | — | | (95,256) | Selling expenses | | — | | (24,817) | | (24,817) | | (2,534) | | — | | (27,351) | Administrative expenses | | (16,395) | | (341) | | (16,736) | | (2,346) | | (11,378) | | (30,460) | Interest income | | 418 | | — | | 418 | | 116 | | 20,040 | | 20,574 | Interest expense | | (914) | | — | | (914) | | (362) | | (200) | | (1,476) | Equity in earnings of an equity investee, net of tax | | — | | — | | — | | 33,807 | | — | | 33,807 | Income tax expense | | (579) | | (530) | | (1,109) | | (97) | | (1,680) | | (2,886) | Other segment items | | 4,048 | | (455) | | 3,593 | | 198 | | (488) | | 3,303 | Net (loss)/income attributable to the Company | | (67,837) | | 53,195 | | (14,642) | | 34,149 | | 6,294 | | 25,801 | Depreciation/ amortization | | (6,076) | | — | | (6,076) | | (130) | | (46) | | (6,252) | Additions to non-current assets (other than financial instruments and deferred tax assets) | | 3,763 | | — | | 3,763 | | 1,929 | | 1,234 | | 6,926 |
| | | | | | | | | | | | | | | June 30, 2025 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Total assets | | 209,654 | | 104,056 | | 313,710 | | 156,150 | | 1,306,080 | | 1,775,940 | Property, plant and equipment | | 94,080 | | — | | 94,080 | | 415 | | 78 | | 94,573 | Right-of-use assets | | 1,730 | | — | | 1,730 | | 1,317 | | 832 | | 3,879 | Leasehold land | | 10,883 | | — | | 10,883 | | — | | — | | 10,883 | Intangible asset (note) | | — | | 9,647 | | 9,647 | | — | | — | | 9,647 | Goodwill | | — | | — | | — | | 3,064 | | — | | 3,064 | Investment in an equity investee | | — | | — | | — | | 3,645 | | — | | 3,645 | Investment in equity security | | 5,000 | | — | | 5,000 | | — | | — | | 5,000 |
Note: During the six months ended June 30, 2025, Tazemetostat was granted approval by the National Medical Products Administration of China for the treatment of adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation, triggering a US$10 million milestone payment, and a corresponding intangible asset was recognized. | | | | | | | | | | | | | | | December 31, 2024 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Total assets | | 225,661 | | 88,502 | | 314,163 | | 194,604 | | 765,429 | | 1,274,196 | Property, plant and equipment | | 91,929 | | — | | 91,929 | | 448 | | 121 | | 92,498 | Right-of-use assets | | 1,845 | | — | | 1,845 | | 1,615 | | 1,037 | | 4,497 | Leasehold land | | 10,706 | | — | | 10,706 | | — | | — | | 10,706 | Goodwill | | — | | — | | — | | 2,990 | | — | | 2,990 | Investment in an equity investee | | — | | — | | — | | 77,765 | | — | | 77,765 | Investment in equity security | | 5,000 | | — | | 5,000 | | — | | — | | 5,000 |
|
| Schedule of geographic information |
| | | | | | | Six Months Ended June 30, | | | 2025 | | 2024 | | | | (in US$’000) | Revenue from external customers: | | | | | PRC | | 205,120 | | 229,069 | US and Others | | 72,557 | | 76,612 | | | 277,677 | | 305,681 |
| | | | | | | | | | | | | | | June 30, 2025 | | December 31, 2024 | | | PRC | | US and Others | | Total | | PRC | | US and Others | | Total | | | | (in US$’000) | Total assets | | 1,716,982 | | 58,958 | | 1,775,940 | | 1,212,722 | | 61,474 | | 1,274,196 | Property, plant and equipment | | 94,030 | | 543 | | 94,573 | | 91,849 | | 649 | | 92,498 | Right-of-use assets | | 3,252 | | 627 | | 3,879 | | 4,086 | | 411 | | 4,497 | Leasehold land | | 10,883 | | — | | 10,883 | | 10,706 | | — | | 10,706 | Intangible asset | | 9,647 | | — | | 9,647 | | — | | — | | — | Goodwill | | 3,064 | | — | | 3,064 | | 2,990 | | — | | 2,990 | Investment in an equity investee | | 3,645 | | — | | 3,645 | | 77,765 | | — | | 77,765 | Investment in equity security | | 5,000 | | — | | 5,000 | | 5,000 | | — | | 5,000 |
|